• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    HeartFlow (HTFL) Shares Just Dropped, So What Is Drawing Attention?

    Simply Wall St·11/03/2026 06:18:52
    Listen to the news

    Clinical trial data puts HeartFlow under the spotlight

    HeartFlow (HTFL) moved into focus after new randomized clinical data presented at the TCT conference indicated that CT-guided PCI planning produced outcomes comparable to intravascular ultrasound, while also improving procedure time and contrast use efficiency.

    Investors have had a bumpy ride with HeartFlow lately, with the share price down 7.72% on the day and 4.41% over the past week. It still carries a 30 day share price return of 10.48% and a 90 day share price return of 99.74%, while the 1 year total shareholder return of 60.05% suggests momentum has been strong over a longer stretch as these clinical results and registry updates keep arriving.

    Scan beyond HeartFlow and explore how other AI-focused healthcare players with strong clinical data are positioning themselves in the market with our hand-picked 33 healthcare AI stocks.

    HeartFlow has surged over the past quarter while slipping back in the latest sessions, which puts a simple question in front of you. Does that swing better reflect a changing business or shifting mood, and what does the current price imply?

    Most Popular Narrative: 15% Overvalued

    HeartFlow last closed at $54.49, while the most followed narrative anchors fair value at $47.22. This leaves the shares trading above that framework and puts the burden of proof on future execution and pricing power.

    The analysts have a consensus price target of $47.22 for HeartFlow based on their expectations of its future earnings growth, profit margins and other risk factors.

    In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $419.0 million, earnings will come to $29.9 million, and it would be trading on a PE ratio of 184.3x, assuming you use a discount rate of 8.1%.

    See why 1 investors see HeartFlow as 15% overvalued.

    Result: Fair Value of $47.22 (OVERVALUED)

    Still, HeartFlow’s story can change quickly if coronary CT adoption cools or if plaque analysis coverage and physician uptake lag behind current expectations.

    Find out about the key risks to this HeartFlow narrative.

    Next Steps

    Mixed feelings about HeartFlow so far. If you want to move past the headlines and judge the trade off yourself, start by weighing its 2 key rewards and 3 important warning signs.

    Looking for more investment ideas beyond HeartFlow?

    If HeartFlow has your attention, do not stop here. The same toolkit can help you surface fresh opportunities that fit your own goals and risk limits.